Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161346 | 0.81 | TGFBR1 (0.34) | — | |
| SCHEMBL20090323 | 0.79 | — | — | |
| SCHEMBL2147475 | 0.72 | GABRG2 (0.39) | — | |
| SCHEMBL24053348 | 0.72 | POLB (0.36) | — | |
| SCHEMBL30166423 | 0.72 | POLB (0.36) | — | |
| SCHEMBL19806300 | 0.71 | PIM1 (0.34) | — | |
| SCHEMBL19806573 | 0.69 | TGFBR1 (0.36) | — | |
| SCHEMBL1673128 | 0.68 | — | — | |
| SCHEMBL28875448 | 0.68 | TRPA1 (0.31) | — | |
| SCHEMBL20090333 | 0.67 | IDH1 (0.30) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993594-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11492349-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210179601-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179601-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10941140-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10941140-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190300518-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | Rigal Pharmaceuticals, Inc. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300518-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | Rigal Pharmaceuticals, Inc. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3532470-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | Rigel Pharmaceuticals, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10370367-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370367-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2018089199-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089199-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941140-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-20210179601-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-11492349-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-20190300518-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-11993594-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-20230062818-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
| US-10370367-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | IDH1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.